

deBriefings

SCIENTISTS PROTEST FDA'S SOY PROTEIN RULING

Our publication of "Tragedy and Hype", an article by Sally Fallon and Mary Enig on the politics and health implications of soy products (see NEXUS 7/03, April–May 2000), had quite an impact on readers, particularly those who had been consuming soy for many years without realizing that it was related to their inexplicable health problems.

The article mentioned the work of Daniel Sheehan, PhD, and Daniel Doerge, PhD, from the US Food and Drug Administration's National Center for Toxicological Research, who wrote a protest letter ahead of a new FDA ruling "authorizing the use, on food labels and in food labeling, of health claims on the association between soy protein and reduced risk of coronary heart disease (CHD)". The FDA had come to the conclusion that "soy protein included in a diet low in saturated fat and cholesterol may reduce the risk of CHD by lowering blood cholesterol levels". However, the FDA disregarded contradictory evidence, and the new ruling came into effect on 26 October 1999.

Drs Sheehan and Doerge were interviewed for the ABC's 20/20 program in the US, broadcast on 9 June and since screened widely around the world. The program looked at the controversy over the safety of soy products as a healthy source of protein, focusing on the relationship between soy and breast cancer in women, accelerated brain ageing in men and developmental disorders in infants. The two researchers told 20/20 that they had tried in vain to stop the FDA's recommendation because it could be misinterpreted as a broader general endorsement beyond solely having benefits for the heart. (For program summary, see http://abc-news.go.com/onair/2020/2020_000609_soy_feature.html.)

The following is the text of their letter dated 18 February 1999. (Please note that while it does refer to a number of studies involving animals, we would like to make it clear that NEXUS in no way condones or supports the efficacy, validity or morality of animal experimentation or vivisection.)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service Food and Drug Administration
National Center For Toxicological Research
Jefferson, Ark. 72079-9502

Daniel M. Sheehan, PhD
Director, Estrogen Base Program
Division of Genetic and Reproductive Toxicology
and

Daniel R. Doerge, PhD
Division of Biochemical Toxicology

February 18, 1999

Dockets Management Branch (HFA-305)
Food and Drug Administration
Rockville, MD 20852


To whom it may concern,

We are writing in reference to Docket #98P-0683; "Food Labeling: Health Claims; Soy Protein and Coronary Heart Disease". We oppose this health claim because there is abundant evidence that some of the isoflavones found in soy, including genistein and equol, a metabolize of daidzein, demonstrate toxicity in estrogen-sensitive tissues and in the thyroid. This is true for a number of species, including humans. Additionally, the adverse effects in humans occur in several tissues and, apparently, by several distinct mechanisms.

Genistein is clearly estrogenic; it possesses the chemical structural features necessary for estrogenic activity (Sheehan and Medlock, 1995; Tong et al., 1997; Miksicek, 1998) and induces estrogenic responses in developing and adult animals and in adult humans. In rodents, equol is estrogenic and acts as an estrogenic endocrine disrupter during development (Medlock et al., 1995a,b). Faber and Hughes (1993) showed alterations in LH regulation following developmental treatment with genistein. Thus, during pregnancy in humans, isoflavones *per se* could be a risk factor for abnormal brain and reproductive tract development. Furthermore, pregnant rhesus monkeys fed genistein had serum estradiol levels 50–100 per cent higher than the controls in three different areas of the maternal circulation (Harrison et al., 1998). Given that the rhesus monkey is the best experimental model for humans, and that a woman's own estrogens are a very significant risk factor for breast cancer, it is unreasonable to approve the health claim until complete safety studies of soy protein are conducted.

Of equally grave concern is the finding that the fetuses of genistein-fed monkeys had a 70 per cent higher serum estradiol level than did the controls (Harrison et al., 1998). Development is recognized as the most sensitive life-stage for estrogen toxicity because of the indisputable evidence of a very wide variety of frank malformations and serious functional deficits in experimental animals and humans. In the human population, DES exposure stands as a prime example of adverse estrogenic effects during development. About 50 per cent of the female offspring and a smaller fraction of male offspring displayed one or more malformations in the reproductive tract, as well as a lower prevalence (about one in a thousand) of malignancies. In adults, genistein could be a

UNTAPPED AD SPACE #1



deBriefings

risk factor for a number of estrogen-associated diseases.

Even without the evidence of elevated serum estradiol levels in rhesus fetuses, potency and dose differences between DES and the soy isoflavones do not provide any assurance that the soy protein isoflavones *per se* will be without adverse effects. First, calculations based on the literature show that doses of soy protein isoflavones used in clinical trials which demonstrated estrogenic effects were as potent as low but active doses of DES in rhesus monkeys (Sheehan, unpublished data). Second, we have recently shown that estradiol shows no threshold in an extremely large dose-response experiment (Sheehan et al., 1999), and we subsequently have found 31 dose-response curves for hormone-mimicking chemicals that also fail to show a threshold (Sheehan, 1998a). Our conclusions are that no dose is without risk; the extent of risk is simply a function of dose. These two features support and extend the conclusion that it is inappropriate to allow health claims for soy protein isolate.

Additionally, isoflavones are inhibitors of the thyroid peroxidase which makes T3 and T4. Inhibition can be expected to generate thyroid abnormalities, including goiter and autoimmune thyroiditis. There exists a significant body of animal data that demonstrates goitrogenic and even carcinogenic effects of soy products (Kimura et al., 1976). Moreover, there are significant reports of goitrogenic effects from soy consumption in human infants (Van Wyk et al., 1959; Hydovitz, 1960; Shepard et al., 1960; Pinchers et al., 1965; Chorazy et al., 1995) and adults (McCarrison, 1933; Ishizuki et al., 1991). Recently, we have identified genistein and daidzein as the goitrogenic isoflavonoid components of soy and defined the mechanisms for inhibition of thyroid peroxidase (TPO)-catalyzed thyroid hormone synthesis *in vitro* (Divi et al., 1997; Divi et al., 1996). The observed suicide inactivation of TPO by isoflavones, through covalent binding to TPO, raises the possibility of neoantigen formation and because anti-TPO is the principal autoantibody present in autoimmune thyroid disease. This hypothetical mechanism is consistent with the reports of Fort et al. (1986, 1990) of a doubling of risk for autoimmune thyroiditis in children who had received soy formulas as infants compared to infants receiving other forms of milk.

The serum levels of isoflavones in infants receiving soy formula are about five times higher than in women receiving soy supplements who show menstrual cycle disturbances including an increased estradiol level in the follicular phase (Setchell, et al., 1997). Assuming a dose-dependent risk, it is unreasonable to assert that the infant findings are irrelevant to adults who may consume smaller amounts of isoflavones. Additionally, while there is an unambiguous biological effect on

menstrual cycle length (Cassidy et al., 1994), it is unclear whether the soy effects are beneficial or adverse. Furthermore, we need to be concerned about transplacental passage of isoflavones, as the DES case has shown us that estrogens can pass the placenta. No such studies have been conducted with genistein in humans or primates. As all estrogens which have been studied carefully in human populations are two-edged swords in humans (Sheehan and Medlock, 1995; Sheehan, 1997), with both beneficial and adverse effects resulting from the administration of the same estrogen, it is likely that the same characteristic is shared by the isoflavones. The animal data is also consistent with adverse effects in humans.

Finally, initial data from a robust (7,000 men), long-term (30+ years) prospective epidemiological study in Hawaii showed that Alzheimer's disease prevalence in Hawaiian men was similar to European-ancestry Americans and to Japanese (White et al., 1996a). In contrast, vascular dementia prevalence is similar in Hawaii and Japan and both are higher than in European-ancestry Americans. This suggests that common ancestry or environmental factors in Japan and Hawaii are responsible for the higher prevalence of vascular dementia in these locations. Subsequently, this same group showed a significant dose-dependent risk

Subsequently, this same group showed a significant dose-dependent risk (up to 2.4-fold) for development of vascular dementia and brain atrophy from consumption of tofu, a soy product rich in isoflavones.

(up to 2.4-fold) for development of vascular dementia and brain atrophy from consumption of tofu, a soy product rich in isoflavones (White et al., 1996b). This finding is consistent with the environmental causation suggested from the earlier analysis, and provides evidence that soy (tofu) phytoestrogens cause vascular dementia. Given that estrogens are important for maintenance of brain function in women, that the male brain contains aromatase, the enzyme that converts testosterone to estradiol, and that isoflavones inhibit this

enzymatic activity (Irvine, 1998), there is a mechanistic basis for the human findings. Given the great difficulty in discerning the relationship between exposures and long-latency adverse effects in the human population (Sheehan, 1998b) and the potential mechanistic explanation for the epidemiological findings, this is an important study. It is one of the more robust, well-designed prospective epidemiological studies generally available. We rarely have such power in human studies, as well as a potential mechanism, and thus the results should be interpreted in this context.

Does the Asian experience provide us with reassurance that isoflavones are safe? A review of several examples led to the conclusion, "Given the parallels with herbal medicines with respect to attitudes, monitoring deficiencies and the general difficulty of detecting toxicities with long latencies, I am unconvinced that the long history of apparent safe use of soy products can provide confidence that they are indeed without

deBriefings

risk" (Sheehan, 1998b). It should also be noted that the claim on p. 62978 that soy protein foods are GRAS [Generally Recognized As Safe] is in conflict with the recent return by CFSAN [Center for Food Safety and Applied Nutrition, FDA] to Archer Daniels Midland of a petition for GRAS status for soy protein because of deficiencies in reporting adverse effects in the petition. Thus GRAS status has not been granted. Linda Kahl can provide you with details. It would seem appropriate for FDA to speak with a single voice regarding soy protein isolate.

Taken together, the findings presented here are self-consistent and demonstrate that genistein and other isoflavones can have adverse effects in a variety of species, including humans. Animal studies are the front line in evaluating toxicity as they predict, with good accuracy, adverse effects in humans. For the isoflavones, we additionally have evidence of two types of adverse effects in humans, despite the very few studies that have addressed this subject. While isoflavones may have beneficial effects at some ages or circumstances, this cannot be assumed to be true at all ages. Isoflavones are like other estrogens in that they are two-edged swords, conferring both benefits and risk (Sheehan and Medlock, 1995; Sheehan, 1997). The health

labeling of soy protein isolate for foods needs to be considered just as would the addition of any estrogen or goitrogen to foods, which are bad ideas.

Estrogenic and goitrogenic drugs are regulated by FDA, and are taken under a physician's care. Patients are informed of risks, and are monitored by their physicians for evidence of toxicity. There are no similar safeguards in place for foods, so the public will be put at potential risk from soy isoflavones in soy protein isolate without adequate warning and information.

Finally, NCTR is currently conducting a long-term multigeneration study of genistein administered in feed to rats. The analysis of the dose-range-finding studies are near-complete or complete now. As preliminary data, which is still confidential, may be relevant to your decision, I suggest you contact Dr Barry Delclos at the address on the letterhead, or e-mail him.

Sincerely,
Daniel M. Sheehan
Daniel R. Doerge

Enclosures
cc: Dr Bernard Schwetz, Director, NCTR
cc: Dr Barry Delclos

References

- Cassidy, A., Bingham, S. and Setchell, K.D.R., "Biological effects of soy protein rich in isoflavones on the menstrual cycle of premenopausal women", *Am. J. Clin. Nutr.* 60:333-340, 1994.
- Chorazy, P.A., Himelhoch, S., Hopwood, N.J., Greger, N.G. and Postellon, D.C., "Persistent hypothyroidism in an infant receiving a soy formula: Case report and review of the literature", *Pediatrics* 148-150, 1995.
- Divi, R.L., Chang, H.C. and Doerge, D.R., "Identification, characterization and mechanisms of anti-thyroid activity of isoflavones from soybean", *Biochem. Pharmacol.* 54:1087-1096, 1997.
- Divi, R.L. and Doerge, D.R., "Inhibition of thyroid peroxidase by dietary flavonoids", *Chem. Res. Toxicol.* 9:16-23, 1996.
- Fort, P., Lanes, R., Dahlem, S., Reeker, B., Weyman-Daum, M., Pugliese, M. and Lifshitz, F., "Breast feeding and insulin-dependent diabetes mellitus in children", *J. Am. Coll. Nutr.* 5:439-441, 1986.
- Fort, P., Moses, N., Fasano, M., Goldberg, T. and Lifshitz, F., "Breast and soy-formula feedings in early infancy and the prevalence of autoimmune thyroid disease in children", *J. Am. Coll. Nutr.* 9:164-167, 1990.
- Harrison, R.M., Phillippi, P.P. and Henson, M.C., "Effects of genistein on estradiol production in pregnant rhesus monkeys (*Macaca mulatta*)", *Am. J. Primatology* 45:183, 1998.
- Hydovitz, J.D., "Occurrence of goiter in an infant on a soy diet", *New Eng. J. Med.* 262:351-353, 1960.
- Irvine, C.H.G., Fitzpatrick, M.G. and Alexander, S.L., "Phytoestrogens in soy-based infant foods: Concentrations, daily intake, and possible biological effects", *Proc. Soc. Exp. Biol. Med.* 217:247-253, 1998.
- Ishizuki, Y., Hirooka, Y., Murata, Y. and Togasho, K., "The effects on the thyroid gland of soybeans administered experimentally to healthy subjects", *Nippon Naibunpi gakkai Zasshi* 67:622-629, 1991.
- Kimura, S., Suwa, J., Ito, B. and Sate, H., "Development of malignant goiter by defatted soybean with iodine-free diet in rats", *Gann.* 67:763-765, 1976.
- Levy, J.R., Faber, F.A., Ayyash, L. and Hughes, C.L., "The effect of prenatal exposure to phytoestrogen genistein on sexual differentiation in rats", *Proc. Soc. Exp. Biol. Med.* 208:60-66, 1995.
- McCarrison, R., "The goitrogenic action of soybean and groundnut", *Indian J. Med. Res.* 21:179-181, 1933.
- Medlock, K.L., Branham, W.S. and Sheehan, D.M., "The effects of phytoestrogens on neonatal rat uterine growth and development", *Proc. Soc. Exp. Biol. Med.* 208:307-313, 1995.
- Medlock, K.L., Branham, W.S. and Sheehan, D.M., "Effects of coumestrol and equol on the developing reproductive tract of the rat", *Proc. Soc. Exp. Biol. Med.* 208:67-1, 1995.
- Miksicek, R.J., "Estrogenic flavonoids: Structural requirements for biological activity", *Proc. Soc. Exp. Biol. Med.* 208:44-50, 1995.
- Pinchers, A., MacGillivray, M.H., Crawford, J.D. and Freeman, A.G., "Thyroid refractoriness in an athyreotic cretin fed soybean formula", *New Eng. J. Med.* 265:83-87, 1965.
- Setchell, K.D.R., Zimmer-Nechemias, L., Cai, J. and Heubi, J.E., "Exposure of infants to phytoestrogens from soy-based infant formula", *Lancet* 350:23-27, 1997.
- Sheehan, D.M., "Literature analysis of no-threshold dose-response curves for endocrine disruptors", *Teratology* 57:219, 1998a.
- Sheehan, D.M., "Herbal medicines and phytoestrogens: risk-benefit considerations", *Proc. Soc. Exp. Biol. Med.* 217:379-385, 1998b.
- Sheehan, D.M., "Isoflavone content of breast milk and soy formulas: Benefits and risks", *Clin. Chem.* 43:850, 1997.
- Sheehan, D.M. and Medlock, K.L., "Current issues regarding phytoestrogens", *Polyphenols Actualities* 13:22-24, 1995.
- Sheehan, D. M., Willingham, E., Gaylor, D., Bergeron, J. M. and Crews, D., "No threshold dose for oestradiol-induced sex reversal of turtle embryos: How little is too much?" *Environmental Health Perspectives*, February 1999.
- Shepard, T.H., Pyne, G.E., Kirschvink, J.F. and McLean, C.M., "Soybean goiter", *New Eng. J. Med.* 262:1099-1103, 1960.
- Tong, W., Perkins, R., Xing, L., Welsh, W.J. and Sheehan, D.M., "QSAR models for binding of estrogenic compounds to estrogen receptor alpha and beta subtypes", *Endo.* 138:4022-4025, 1997.
- Van Wyk, J.J., Arnold, M.B., Wynn, J. and Pepper, F., "The effects of a soybean product on thyroid function in humans", *Pediatrics* 24:752-760, 1959.
- White, L., Petrovitch, H., Ross, G.W. and Masaki, K.H., "Association of mid-life consumption of tofu with late life cognitive impairment and dementia: The Honolulu-Asia Aging Study", *The Neurobiol. of Aging* 17(suppl. 4):S121, 1996a.
- White, L., Petrovitch, H., Ross, G.W., Masaki, K.H., Abbot, R.D., Teng, E.L., Rodriguez, B.L., Blanchette, P.L., Havlik, R.J., Wergowske, G., Chiu, D., Foley, D.J., Murdaugh, C. and Curb, J.D., "Prevalence of dementia in older Japanese-American men in Hawaii", *JAMA* 276:955-960, 1996b.